Remibrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, showed promising results in improving chronic spontaneous urticaria symptoms in patients who did not respond to H1 antihistamines. Studies found that patients experienced significant improvements in urticaria activity, itch severity, and hives severity with remibrutinib treatment, with over 50% of patients achieving minimal important differences in their symptoms. The drug works by preventing mast cell release of histamine and other mediators, providing a novel treatment option for patients with inadequately controlled chronic spontaneous urticaria. Researchers believe remibrutinib could be an effective and safe treatment for this condition.
Source link
Chronic spontaneous urticaria symptoms improve in 1 week with remibrutinib
